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Abstract
Ank is a multipass transmembrane protein that regulates the
cellular transport of inorganic pyrophosphate. In the progressive
ankylosis (ank) mouse, a premature termination mutation at
glutamic acid 440 results in a phenotype characterized by
inappropriate deposition of basic calcium phosphate crystals in
skeletal tissues. Mutations in the amino terminus of ANKH, the
human homolog of Ank, result in familial calcium pyrophosphate
dihydrate deposition disease. It has been hypothesized that
these mutations result in a gain-of-function with respect to the
elaboration of extracellular inorganic pyrophosphate. To explore
this issue in a mineralization-competent system, we stably
transduced ATDC5 cells with wild-type Ank as well as with
familial chondrocalcinosis-causing Ank mutations. We
evaluated the elaboration of inorganic pyrophosphate, the
activity of pyrophosphate-modulating enzymes, and the
mineralization in the transduced cells. Expression of transduced
protein was confirmed by quantitative real-time PCR and by
ELISA. Levels of inorganic pyrophosphate were measured, as
were the activities of nucleotide pyrophosphatase
phosphodiesterase and alkaline phosphatase. We also
evaluated the expression of markers of chondrocyte maturation
and the nature of the mineralization phase elaborated by
transduced cells. The cell line expressing the proline to leucine
mutation at position 5 (P5L) consistently displayed higher levels
of extracellular inorganic pyrophosphate and higher
phosphodiesterase activity than the other transduced lines.
During hypertrophy, however, extracellular inorganic
pyrophosphate levels were modulated by alkaline phosphatase
activity in this cell system, resulting in the deposition of basic
calcium phosphate crystals only in all transduced cell lines. Cells
overexpressing wild-type Ank displayed a higher level of
expression of type X collagen than cells transduced with mutant
Ank. Other markers of hypertrophy and terminal differentiation,
such as alkaline phosphatase, osteopontin, and runx2, were not
significantly different in cells expressing wild-type or mutant Ank
in comparison with cells transduced with an empty vector or
with untransduced cells. These results suggest that the P5L Ank
mutant is capable of demonstrating a gain-of-function with
respect to extracellular inorganic pyrophosphate elaboration,
but this effect is modified by high levels of expression of alkaline
phosphatase in ATDC5 cells during hypertrophy and terminal
differentiation, resulting in the deposition of basic calcium
phosphate crystals.
Introduction
The pathologic deposition of calcium pyrophosphate dihy-
drate crystals in the joints of patients with familial chondrocal-
cinosis is associated with mutations in ANKH (for a review,
see [1]). The ANKH gene is the human homologue of the gene
responsible for progressive ankylosis in a naturally occurring
mutant mouse [2]. The product of the ank/ANKH gene
appears to regulate the transport of inorganic pyrophosphate
(PPi) through the cell membrane. Sohn and colleagues origi-
nally observed high expression of Ank in the hypertrophic
ank = progressive ankylosis gene/cDNA (murine); Ank = progressive ankylosis protein (murine); ANK = progressive ankylosis protein (human); ANKH 
= progressive ankylosis gene (human); AP = alkaline phosphatase; bp = base pair; col2a1 = gene coding for type II collagen (murine); col10a1 = 
gene coding for type X collagen (murine); CPPD = calcium pyrophosphate dihydrate deposition; DMEM = Dulbecco's modified Eagle's medium; 
ELISA = enzyme-linked immunosorbent assay; ePPi = extracellular inorganic pyrophosphate; iPPi = intracellular inorganic pyrophosphate; M48T = 
methionine position 48 to threonine; NPP = nucleotide pyrophosphatase phosphodiesterase; P5L = proline position 5 to leucine; P5T = proline posi-
tion 5 to threonine; PCR = polymerase chain reaction; PPi = inorganic pyrophosphate; RT = reverse transcriptase.Arthritis Research & Therapy    Vol 8 No 6    Zaka et al.
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growth plate [3]. Interestingly, high levels of ANKH expression
have also been found in osteoarthritic cartilage and in cartilage
from patients with calcium pyrophosphate dihydrate deposi-
tion (CPPD), particularly in areas of cartilage tissue that are
populated with hypertrophic-like chondrocytes [4-6]. While
these observations suggest that Ank plays a role in the patho-
logical mineralization of cartilage, Wang and colleagues [7]
have shown that the protein also has an important role in the
physiological mineralization of the chick tibial growth plate by
demonstrating that increased Ank activity led to decreased
levels of extracellular PPi resulting from the concomitant
upregulation of alkaline phosphatase (AP) expression.
To characterize the role of wild-type Ank and its mutants in the
regulation of PPi transport in vitro, we stably transduced
ATDC5 cells with wild-type Ank and three missense mutations
we have reported in families with familial chondrocalcinosis.
We chose to only modestly overexpress wild-type and mutant
Ank in order to create a stable dominant-negative environment
in which to evaluate PPi elaboration, as well as the activity of
two enzymes that are critical to the fate of PPi generation:
nucleotide pyrophosphohydrolase phosphodiesterase (NPP)
and AP. These studies were performed in ATDC5 cells to take
advantage of the fact that these well-characterized cells are
fully mineralization competent [8] and are amenable to stable
transfection. Furthermore, the use ofATDC5 cells permitted us
to address some critical issues concerning the biochemical
and physiological impact of overexpression of wild-type Ank,
and the expression of mutant forms of Ank, on the course of
chondrogenesis.
Materials and methods
Cell culture, proliferation assays, and gene expression 
studies
ATDC5 cells [9] (3 × 104 cells/35 mm dish) were maintained
in DMEM/Ham's F-12 (1:1) containing 5% fetal bovine serum,
2 mM L-glutamine, 10 μg/ml human transferrin, and 3 × 10-8
M sodium selenite (maintenance medium), or the cells were
differentiated, without passage, in the same medium supple-
mented with 10 μg/ml insulin (chondrogenic medium). The
media were changed every other day. Proliferation of untrans-
duced cells or transduced cells was monitored using the cell
proliferation agent WST-1 (Roche, Indianapolis, IN, USA).
Cells were propagated in 96-well plates at the same cell den-
sity as described above. Following addition of WST-1 reagent,
the optical density was read at 450 nm. The background was
determined by assay of clean media collected at equivalent
time points.
For studies of mineralization in ATDC5 cells, at day 21 of cul-
ture, α-MEM medium containing 5% fetal bovine serum 2 mM
glutamine, 10 μg/ml human transferrin, 3 × 10-8 M sodium
selenite, and 10 μg/ml insulin was added to the cell cultures
without passage of cells. The concentration of CO2 was also
switched to 3%, as previously described [8]. The medium was
replaced every other day. For measurements of mineral con-
tent by Fourier transform IR analyses, cell layers were washed
with phosphate-buffered saline, scraped into 0.1 M ammo-
nium bicarbonate solution (pH 8.5), pelleted, and lyophilized.
For experiments in which the constitutive expression of ank
was assessed, cells were incubated in parallel cultures con-
taining maintenance medium and chondrogenic medium for a
period of 21 days. Cells were harvested at the times indicated
above for poly A+ RNA isolation using the Micro-FastTrack 2.0
kit according to manufacturer's specifications (Invitrogen,
Carlsbad, CA, USA). For cDNA synthesis, 150 ng mRNA was
reverse transcribed using the ThermoScript RT-PCR system
(Invitrogen). The resultant cDNA was utilized for quantitative
RT-PCR, using β-actin as standard. The primers used to
amplify ank were sense primer 5' -cttctagcagggtttgtggg-3' (in
exon 11 of the transcript) and antisense primer 5' -tcgtctctttc-
ctcctcctc-3' (in the 3' -untranslated region; product = 166 bp).
Thermocycling was performed in a MyIQ thermocycler (Bio-
rad, Hercules, CA, USA) using a reaction mix containing syber
green. A melting curve was performed for each PCR cycling
reaction to ensure recovery of a single syber green fluorescing
species in the reaction product. The fold changes of steady-
state RNA levels were determined by the formula 2-ddCt, where
ddCt = dE – dC (dE = Ctexp – Ctactin and dC = Ctcontl – Ctactin;
dE = delta experimental, dC = delta control, Ct = cycling
threshold).
Preparation of FLAG-tagged Ank constructs and 
transient transfection with FLAG-tagged constructs
The wild-type sequence of murine ank was used for both tran-
sient and stable cDNA constructs of ank, and all mutations in
ank  were prepared in the context of the mouse cDNA
sequence. Ank cDNA was subcloned into a pcDNA I vector
(Invitrogen) containing a FLAG sequence at the amino termi-
nus of the multiple cloning site. To generate an inframe FLAG
tag, the stop codon of each Ank cDNA – wild type and the
proline position 5 to leucine (P5L), proline position 5 to threo-
nine (P5T), and methionine position 48 to threonine (M48T)
mutants – was ablated by site-directed mutagenesis and the
FLAG tag was added to the 3' end of each cDNA by the PCR.
The integrity of each construct was confirmed by direct
sequence analysis of the entire cDNA-FLAG insert.
For transfection with pcDNA I/ank-FLAG cDNA constructs,
ATDC5 cells were transfected with wild-type and mutant con-
structs (1 μg plasmid DNA/ml medium) in the presence of
FuGene 6 reagent (Roche) at a ratio of 1 μg plasmid DNA:2.5
μl FuGene 6 reagent. A construct containing the lacZ gene
was prepared as a control for transfection efficiency using the
same lacZ:FuGene6 ratio. After 48 hours of culture in mainte-
nance medium, cells were fixed with 4% p-formaldehyde and
were immediately processed for immunohistochemistry using
a mouse polyclonal anti-FLAG M2 antibody (Stratagene, La
Jolla, CA, USA). and goat anti-mouse secondary IgG antibodyAvailable online http://arthritis-research.com/content/8/6/R164
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conjugated to Alexa fluor 488 (Molecular Probes, Eugene, OR,
USA). Parallel chamber slides were incubated in secondary
antibody only. Cells were mounted with VectaShield (Vector
Laboratories, Inc., Burlingame, CA, USA) mounting medium
with propidium iodide for fluorescent detection of double-
stranded DNA, and the cells were then visualized on a Zeiss
LSM510 Mera confocal microscope (Carl Zeiss MicroImag-
ing, Thornwood, NY, USA) using a 63x lens.
Preparation of retroviral Ank constructs and stable 
transduction of ATDC5 cells
For the preparation of stable transfections via retroviral trans-
duction, ank cDNA wild-type and mutant constructs, prepared
in the context of the mouse cDNA sequence, were subcloned
into the pLNCX expression vector (Clontech, Palo Alto, CA,
USA) and were packaged as directed by the manufacturer.
Virus-containing medium was directly added to ATDC5 cells
that had been plated to 80% confluence in maintenance
medium 24 hours prior to infection. After 24 hours cells were
subjected to selection with the neomycin resistance reagent
G418 (350 μg G418/ml media) for 2 weeks (media were
changed every 4 days). Approximately 10% of cells survived
selection and were expanded at low density in 100 μg G418/
ml media and were further subjected to clonal selection. Cells
were expanded in the presence of G418 to ensure retention
of the transduced cDNAs, and were eventually harvested for
mRNA isolation to evaluate relative expression of endogenous
and transduced cDNAs.
DNA was also isolated and used in Southern blot analyses to
confirm the clonality of the cell lines. Genomic DNA was
cleaved with XbaI (an enzyme that cleaves only once in the
pLNCX vector in the 3' long terminal repeat region), blotted,
and probed with a PCR product derived from the cytomegalo-
virus promoter region of the pLNCX vector to exclude detec-
tion of endogenous ank sequences.
Detection of expression of transduced Ank in ATDC5 
cells by real-time PCR
Real-time PCR was used to measure levels of both endog-
enous and transduced ank  transcripts in clonally selected
populations. For detection of transduced wild-type or mutant
ank transcripts, PCR primers were derived from sequences
between exons 11 and 12 of the ank cDNA (sense primer, 5'
-ggtttgtgggagaatctacc-3'); the antisense primer was derived
from the pLNCX vector (5' -ccccctttttctggagacta-3' ; product
size = 265 bp). For detection of endogenous ank transcript,
the primers described earlier in Materials and methods were
used. The ratio of PCR products was determined by compari-
son of the ddCt values for the endogenous transcript divided
by the ddCt for the transduced transcript, as previously
described. For each cloned transductant, four separate clones
expressing a 1:1 ratio of endogenous to transduced transcript
were independently evaluated for Ank protein expression.
ELISA determination of Ank protein expression in stably 
transduced cells
Cells were harvested, in the presence of protease inhibitor,
from confluent cultures of transduced cells and were dis-
rupted by rapid freeze/thaw with final dispersion through an
18-gauge needle. Protein was quantitated by the Bradford
Coomassie assay (Pierce, Rockford, IL, USA), using bovine
serum albumin as the standard.
Polyclonal anti-Ank antisera were generated (Cocalico, Bio-
logicals Inc., Westville, PA, USA) in Leghorn chickens against
a synthetic peptide immunogen derived from the Ank carboxy
terminus conjugated to keyhole limpet hemocyanin, as previ-
ously described [2] for the preparation of an Ank-specific
antiserum. Ammonium sulfate-precipitated chicken antibody
derived from blood sera was delipidated with n-butanol/diiso-
propyl ether in a 40:60 (vol/vol) ratio [10].
ELISA procedures relevant to the determination of antibody or
antigen titers using a twofold dilution series have been
described [11]. Primary antibody binding to antigens was
detected with an affinity-purified, peroxidase-conjugated don-
key anti-chicken IgY (Jackson Immunoresearch Laboratories,
Inc., West Grove, PA, USA) at a dilution of 1:5,000. The sec-
ondary antibody was then quantitated with a chromogenic
substrate, o-phenylenediamine, and the optical densities at
490 nm were recorded with a microplate reader (Opsis MR
Microplate Reader; Thermo/Labsystems, Waltham. MA, USA)
using Revelation Quicklink software (Dynex Technologies,
Chantilly, VA, USA).
Intracellular and extracellular inorganic pyrophosphate 
assays
For studies of extracellular inorganic pyrophosphate (ePPi)
and intracellular inorganic pyrophosphate (iPPi) elaboration in
cells undergoing differentiation, as well as for measurements
of AP and NPP activities, and measurement of expression of
markers of hypertrophy (see below), cells were cultured in dif-
ferentiation medium until 24 hours prior to assay. At this time,
media for cells to be assayed were refreshed with mainte-
nance medium (which does not contain insulin).
For assay of iPPi, cells were harvested heated at 65°C for 1
hour and were lysed in lysis buffer containing 1% Triton X-100,
1.6 mM MgCl2, and 0.2 M Tris, pH 8.0. For assay of ePPi,
media were cleared of cellular debris and were diluted 1:2 in
lysis buffer. PPi levels were evaluated by the enzymatic proce-
dure of Lust and Seegmiller [12], as modified by Johnson and
colleagues [13], where PPi is determined by differential
absorption on activated charcoal of UDP-D- [6-3H]-glucose
from the reaction product 6-phospho- [6-3H]-gluconate. All
assay results were normalized versus DNA concentration
using a Pico Green assay of double-stranded DNA (Molecular
Probes).Arthritis Research & Therapy    Vol 8 No 6    Zaka et al.
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Assays of alkaline phosphatase and nucleotide 
pyrophosphohydrolase activity
The diethanolamine enzymatic assay (Sigma, St Louis, MO,
USA) was used to measure the AP (EC 3.1.3.1) activity [14].
Cells were disrupted, were reacted with substrate solution
containing a final concentration of 15 mM p-nitrophenyl phos-
phate in the presence of 1 M diethanolamine and 0.5 mM
MgCl2, pH 9.8, and the optical densities of the reaction prod-
uct (p-nitrophenol) were determined at 405 nm at time 0 and
at 1 and 2 minutes after the start of the reaction. The AP activ-
ity was normalized to the total protein concentration of diluted
cell lysates as determined by use of the BCA Protein assay
(Pierce). Inhibition of AP activity was performed with the addi-
tion of 3 μM levamisole, which was added to the cell culture
medium for 72 hours prior to harvesting for AP activity meas-
urements.
For the assay of NPP (EC 3.6.1.8, EC 3.1.4.1) activity, 1 mM
p-nitrophenyl-thymidine 5' -monophosphate (Sigma) was used
as substrate in a reaction to which 5 μl cell lysate was added
[13]. A standard curve consisting of p-nitrophenol in 50 mM
Hepes-buffered DMEM and 1.6 mM MgCl2 was also prepared.
Reactions were terminated by the addition of 55 μl of 0.1 M
NaOH, and optical densities were determined at 405 nm. Final
sample comparisons were expressed as units per milligram of
total protein.
Expression of markers of chondrocyte maturation and 
terminal differentiation
To monitor the differentiation of transduced cells, poly A+
RNA was used in real-time RT-PCR to detect the expression
of type II collagen (col2a1), of sox9, and of type X collagen
(col10a1). Primers for these transcripts were as follows:
col2a1, sense primer 5' -gagggccaggaggtcctctgg-3' and anti-
sense primer 5' -tcgcggtgagccatgatccgc-3' (product size =
177 bp); col10a1, sense primer 5' -taccacgtgcatgtgaaagg-3'
and antisense primer 5' -ggagccactaggaatcctga-3' (product
size = 236 bp); and sox9, sense primer 5' -agt tga tct gaa gcg
aga ggg-3' and antisense primer 5' -cct ggg tgg ccg ttg ggt
ggc-3' (product size = 169 bp).
Expression levels of additional markers of the hypertrophic
phenotype were measured to evaluate the impact of ank
mutants on hypertrophy in transduced ATDC5 cells. These
additional markers included osteopontin (sense primer 5' -cac
atg aag agc ggt gag tct-3', antisense primer 5' -atc gat cac atc
cga ctg atc-3' ; product size = 198 bp) and runx2 (cbfa1;
sense primer 5' -atggcactctggtcaccgtc-3', antisense primer 5'
-cctgaggtcgttgaatctcg-3' ; product size = 110 bp).
The fold changes of steady-state RNA levels in ank-trans-
duced cells compared with cells transduced with empty vector
only were determined as previously described. Reactions
were performed in triplicate and were repeated twice.
Statistical methods
Data are presented as the mean ± standard deviation. The sta-
tistical significance was identified using the unpaired, two-
tailed Student t test, unless otherwise indicated in the figure
legend (P values reported in the figure legends). All assays
were performed at least in triplicate; see figure legends for the
exact number of replicates performed.
Results
Expression of endogenous ank in ATDC5 cells
Before transduction studies were performed, we determined
the endogenous expression of ank in the cell line during a 21-
day course of chondrogenesis, prior to the entry of cells into
hypertrophy. Cells were plated in the presence or absence of
the chondrogenic promoter insulin [9] and mRNA was isolated
for determination of ank expression., The expression of ank
after day 3 of culture was consistent throughout the prolifera-
tion stage in the untransduced cells regardless of the insulin
treatment regimen (data not shown).
Localization of mutant Ank molecules to the cell 
membrane
To confirm that the mutant Ank gene products could appropri-
ately translocate to the cell membrane as has been observed
for wild-type Ank [2], we transiently transfected FLAG-tagged
mutant and wild-type ank constructs into ATDC5 cells. The
mutant  ank  constructs were three missense mutations of
ANKH that occurred in four unrelated CPPD disease families,
as we previously described [15-17], and whose sequence and
sequence contexts were fully conserved in the murine
sequence. The missense mutations included the P5T and P5L
substitutions, occurring at positions +13 bp and +14 bp of the
Ank cDNA, respectively, and the M48T substitution, occurring
at position +143 of the ank cDNA. Cells expressing mutant
Ank molecules exhibited localization identical to that seen for
wild-type Ank. Figure 1a demonstrates the localization of one
mutant Ank molecule: the M48T mutant. In all cases,
expressed Ank molecules could be visualized at the cell sur-
face by confocal microscopy.
Selection and characterization of clonal populations of 
ATDC5 cells expressing wild-type and mutant Ank
To achieve moderate levels of mutant ank  expression in
ATDC5 cells that were comparable with expression of the
endogenous transcript, we chose to subject our transduced
cells to a further round of selection using limiting dilution.
Clonality was confirmed by Southern blot analysis (data not
shown), and mRNA was isolated and subjected to real-time
RT-PCR with primers specific for either the transduced ank
transcripts or the endogenous ank  transcripts. The clones
were then analyzed for both endogenous and exogenous ank
transcript levels, and clones that exhibited a 1:1 ratio of
endogenous transcript to transduced transcript were selected
for further analysis. For each wild-type or mutant construct,Available online http://arthritis-research.com/content/8/6/R164
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four independent clones exhibiting a 1:1 ratio of transduced to
endogenous transcript were assayed for protein expression.
To ensure that transduced cells were expressing gene prod-
uct derived from the transduced cDNAs, we first considered
the possibility of adding a tag to the transduced cDNAs to fol-
low their expression and translation into protein. We ultimately
wished to use the transduced cell lines for determination of
PPi levels, however, and we were acutely aware of the fact that
minor perturbations in the structure of the Ank protein can
have a major impact on Ank function [2,15,16,18,19]. We
therefore chose to monitor the production of total Ank protein
by a quantitative ELISA assay using a peptide-directed poly-
clonal antibody that was capable of reacting to exposed (that
Figure 1
Transfection of ATDC5 cells with wild type and mutant Ank Transfection of ATDC5 cells with wild type and mutant Ank. (a) Confocal microscopy of ATDC5 cells transiently transfected with M48T mutant 
cDNA. Left panel is phase-contrast image of right panel. All transfected cells showed a similar pattern of plasma cell membrane staining, indicating 
that even mutant Ank molecules were able to translocate to the plasma cell membrane. (b) ELISA assay results showing comparative levels of Ank 
protein expression in ATDC5 cell lysates versus lysates of independent clones of ATDC5 cells transduced with various ank constructs. All cells 
express endogenous Ank protein, but transduced cells also express protein derived from expression of transduced constructs. Data represent quad-
ruplicate assays and are representative of results obtained from other independent clones for each transductant. *P ≤ 0.05. (c) WST-1 proliferation 
assay at day 7 of culture in ATDC5 cells transduced with empty vector and with various wild-type (WT) or mutant ank constructs. At days 7, 14, and 
21, 7.5 μl WST-1 reagent was added directly to 150 μl cell medium and incubated for 1.5 hours at 37°C in 5% CO2. Results at all time points con-
sistently exhibited no significant differences in the proliferation of mutant-transduced cells compared with untransduced cells or cells transduced 
with empty vector. n = 3.Arthritis Research & Therapy    Vol 8 No 6    Zaka et al.
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is, nontransmembrane) epitopes following cell disruption. We
expected clones expressing a 1:1 ratio of endogenous ank
transcript to transduced ank transcript to produce approxi-
mately twice the amount of Ank protein as cells that expressed
endogenous  ank  transcript only. ELISA assays were per-
formed on the cell lines, and the results indicated that clones
transduced with wild-type or mutant ank expressed approxi-
mately twice the level of Ank protein as observed in the origi-
nal, untransduced cells (Figure 1b).
To determine whether transduction of wild-type and mutant
ank constructs affected proliferation of transduced cells, we
determined the proliferation and cell viability based upon the
cleavage of the tetrazolium salt, WST-1, by mitochondrial
dehydrogenases in viable cells. At days 7, 14, and 21 of assay
there were no significant statistical differences in proliferation
and viability in cells transduced with wild-type ank or mutant
ank compared with cells transduced with empty vector (Figure
1c). These results demonstrated that the transduction of ank
did not affect the ability of cells to proliferate normally.
Levels of intracellular and extracellular inorganic 
pyrophosphates in transduced ATDC5 cells
The levels of PPi are variably affected by many growth factors
and cytokines (for a review, see [20]). Because of the reported
effects of insulin-like growth factor 1 on the elaboration of PPi
in chondrocytes [21,22], we chose to eliminate exogenous
insulin from the medium used for the studies of PPi levels in
transduced ATDC5 cells for 24 hours prior to assay. We first
evaluated the impact of overexpression of ank in day 14 (pro-
liferation phase) cells transduced with wild-type ank, but prior
to clonal selection. Overexpression of ank resulted in a statis-
tically significant decrease in iPPi (Figure 2a) and a concomi-
tant increase in ePPi (Figure 2b), as has been previously
reported in COS cells and in bovine chondrocytes [2,6].
We next examined the impact of mutations in Ank on the elab-
oration of ePPi in proliferating ATDC5 clonal cell lines, in non-
mineralizing hypertrophic ATDC5 clonal cell lines, and in
mineralizing ATDC5 clonal cell lines. The results demonstrate
that, during their proliferating phase, all cells stably transduced
with ank exhibit higher levels of extracellular PPi than cells
transduced with empty vector only; however, only cells stably
transduced with the P5L mutant exhibited levels of ePPi signif-
icantly greater than cells transduced with the other mutants or
cells transduced with wild-type Ank (Figure 3a). These same
results were observed for the P5L cell line when ePPi levels
were measured at hypertrophy under nonmineralizing condi-
tions. Also, at hypertrophy there is no statistically significant
difference in ePPi elaboration among cells that were trans-
duced with wild-type Ank and the P5T and M48T mutants in
comparison with cells transduced with empty vector (Figure
3b). Finally, ePPi levels were evaluated from cells that were
mineralized, and we observed a significant increase in ePPi
elaboration in all transduced cells (Figure 3c).
In light of reports suggesting that Ank expression is increased
in regions of cartilage undergoing terminal differentiation and
mineralization, or in response to agents that induce mineraliza-
tion [3,6,7], we explored the possibility that the high levels of
ePPi in mineralized cells might be a function of increased Ank
expression. Figure 3d illustrates that ank expression is roughly
equivalent among the cells lines transduced with wild-type or
mutant ank at all three stages of chondrogenesis; however,
the expression of ank in the transductants increased as the
cells progressed toward mineralized hypertrophy. Notably,
there was an approximately fourfold increase in ank expression
in the transduced cells at mineralized hypertrophy compared
with that in nonmineralized hypertrophic cells. As illustrated in
Figure 3c, in mineralizing conditions we did not observe a sta-
tistically significant increase in ePPi in any of the mutant cell
lines, including the P5L cell line, when compared with cells
transduced with wild-type ank. Additionally, there was no sta-
tistically significant difference in the elaboration of ePPi in cells
that overexpressed wild-type Ank compared with cells trans-
duced with empty vector only.
Our observations were consistent with the previous observa-
tions of Wang and colleagues [7], although not as dramatic as
those they observed. More specifically, Wang and colleagues
observed that retroviral-driven overexpression of Ank in hyper-
trophic chondrocytes actually decreased the elaboration of
ePPi, apparently due to increased activity of AP resulting from
the overexpression of Ank (see below), while, as stated above,
we observed that modest overexpression of Ank did not result
in an increase in the elaboration of ePPi compared with cells
transduced with empty vector only. Since ATDC5 cells have
been shown to elaborate significant amounts of AP during
their mineralization phase [8], we hypothesized that the lack of
ePPi excess in cells overexpressing Ank compared with that in
cells transduced with empty vector, or in the P5L mutant cell
line, may be due to hydrolysis of PPi by AP. We therefore next
evaluated the nature of PPi elaboration at hypertrophy and at
mineralization as a function of AP activity, as well as of NPP
activity.
Alkaline phosphatase and nucleotide 
pyrophosphohydrolase activity activities in ATDC5 cells 
transduced with wild-type and mutant Ank
In the complex regulation of cellular PPi elaboration, two major
enzyme systems play an important role in the generation of
extracellular PPi: NPP, an ecto-enzyme that can hydrolyze
nucleoside triphosphates into their monophosphate esters
and PPi; and AP, an enzyme with pyrophosphatase activity
[23]. We evaluated the levels of both of these enzymes in
transduced cells during the proliferative phase of differentia-
tion (day 14), the nonmineralizing hypertrophic phase of differ-
entiation (day 28), and the mineralization phase of
differentiation (day 35).Available online http://arthritis-research.com/content/8/6/R164
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AP activity was very low during the proliferative stage of
ATDC5 cell chondrogenesis in all of the cell lines tested (Fig-
ure 4); however, its activity increased during both the nonmin-
eralizing hypertrophic phase of differentiation and in
mineralizing cells. Consistent with previous reports of ATDC5
cellular hypertrophy and mineralization [8], the levels of AP
activity increased significantly between day 28 at nonmineral-
izing hypertrophy and day 35 when the cells were mineralized.
Although AP levels were somewhat higher in cells overex-
pressing wild-type ank versus cells transduced with empty
vector only, neither nonmineralizing hypertrophic cells nor min-
eralized cells that had been transduced with mutant ank con-
structs demonstrated significantly different levels of AP activity
to cells overexpressing wild-type ank (Figure 4). The increase
in AP activity in response to the modest overexpression of
wild-type ank was not as great as that observed by Wang and
colleagues in their study of the role of Ank in nonmineralizing
hypertrophic chondrocytes derived from the chick tibia growth
plate [7]. In their study, however, wild-type ank was greatly
overexpressed via retroviral transfection and infection using a
replication competent retrovirus [7]. Nevertheless, the con-
comitant increase in ank expression (see Figure 3d) and in AP
activity was consistent with that observed by Wang and col-
leagues [7].
Activities of the PPi-generating enzyme NPP were also evalu-
ated in proliferating cells, in the nonmineralizing, hypertrophic
cells, and in mineralizing cells that had been transduced with
wild-type and mutant ank at days 14, 28, and 35, respectively.
Figure 4 demonstrates that, in contrast to cells transduced
with wild-type ank and the P5T mutant and M48T mutant Ank,
the P5L mutant cell line consistently exhibited significantly
higher NPP activity during the proliferative, the nonmineralizing
hypertrophic, and the mineralization phases of differentiation.
All of the transduced cells illustrated an increase in NPP activ-
ity at day 35 (mineralization) of culture; this observation was
consistent with previous reports showing that an increase in
AP expression leads to enhanced levels of PC-1, an NPP iso-
form [24].
As already discussed, we observed that increased levels of
ePPi were not present in the P5L cell line when the cells
underwent mineralization, despite the fact that at this stage of
differentiation NPP activity was still elevated in the P5L cells.
Figure 2
Extracellular and intracellular inorganic pyrophosphates in ATDC5 cells transduced with wild-type vector before clonal selection Extracellular and intracellular inorganic pyrophosphates in ATDC5 cells transduced with wild-type vector before clonal selection. Cells were assayed 
at day 14 of chondrogenesis. (a) Consistent with previous reports of the impact of overexpression of ank on levels of intracellular inorganic pyro-
phosphate (iPPi) and extracellular inorganic pyrophosphate (ePPi), cells transduced with wild-type (WT) ank demonstrate a decrease in levels of 
iPPi when compared with cells transduced with pLNCX empty vector or with untransduced ATDC5 cells. (b) Concomitantly, cells transduced with 
WT ank exhibit an increase in ePPi levels when compared with cells transduced with pLNCX vector only (empty) or with untransduced ATDC5 cells. 
n = 6; *P ≤ 0.05. PPi, inorganic pyrophosphate.Arthritis Research & Therapy    Vol 8 No 6    Zaka et al.
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We therefore hypothesized that, during mineralization, high
levels of AP activity may have resulted in the hydrolysis of the
NPP-driven excess of ePPi in the P5L cell line. To test this
hypothesis, the P5L cells were treated with levamisole, an
inhibitor of AP activity. Figure 5a,b illustrates that treatment of
the P5L cell line with levamisole inhibited AP activity, and
resulted in an increase in ePPi in the P5L cells, suggesting that
excess ePPi is being hydrolyzed by AP during the mineraliza-
tion phase. Although depression of AP activity was dramatic,
the data suggest that approximately 25% of ePPi was hydro-
lyzed by AP. These findings are consistent with the trend
toward a higher level of ePPi in the P5L cell line during miner-
alization – although, as discussed above, this trend was not
statistically significant (Figure 3c). The failure of AP to further
hydrolyze ePPi may relate to the rate of hydrolysis of ePPi by
AP in the cell line; however, we did not evaluate the kinetics of
ePPi hydrolysis in the current study.
Taken together, our data suggest that at day 35 (mineralizing
hypertrophy) neither NPP nor AP are entirely responsible for
the high levels of ePPi elaboration among the ank-transduced
cell lines (Figure 3c), including the P5L cell line. Rather, the
results strongly suggest that the increase in ePPi elaboration
in the ank-transduced cells during the mineralizing hyper-
trophic stage of chondrogenesis at day 35 is a reflection of the
increase in transport activity of Ank (that is, higher levels of ank
expression).
Effect of ank overexpression, and expression of mutant 
ank on the hypertrophic phenotype in transduced ATDC5 
cells
Since studies of idiopathic CPPD disease have suggested
that the pathological mineralization of articular cartilage may
occur in a matrix that expresses many markers of chondrocyte
hypertrophy [5,25], we took advantage of the fact that ATDC5
cells are capable of undergoing a complete course of
chondrocyte maturation that would enable us to monitor the
course of chondrogenesis in the ank-transduced cells. As
reported previously [8], the synthesis of col2a1 reached max-
imal levels at day 14 of culture. At 28 days of culture, all cells
– whether transduced with empty vector, with wild-type Ank,
or with mutant Ank – were morphologically hypertrophic and
exhibited a decrease in col2a1 and sox9 expression levels
compared with the levels observed in transduced cells at their
proliferative phase (data not shown), with a comcomitant
increase in expression of col10a1 that peaked at 35 days of
culture [8]. These observations showed that stably transduced
cells were fully competent to appropriately undergo a course
of chondrogenesis, thus indicating that retroviral transduction
did not influence the course of chondrogenic differentiation in
the cells.
To determine whether the expression of mutant ank affected
the course of chondrocyte maturation in the transduced cells,
we performed real-time RT-PCR to assess the expression of
Figure 3
Expression of Ank and generation of extracellular PPi in transduced  ATDC5 cells Expression of Ank and generation of extracellular PPi in transduced 
ATDC5 cells. (a) Extracellular inorganic pyrophosphate (ePPi) levels in 
various ATDC5 clonal cell lines at day 14 of chondrogenesis. Empty, 
uncloned ATDC5 cells transduced with pLNCX vector only; WT, wild-
type ank. *Significance of ePPi levels of WT and mutant Ank-trans-
duced cell lines versus cells transduced with empty vector only. #Sig-
nificance of P5L ePPi levels versus cells transduced with WT Ank or 
mutant ank constructs, as indicated. (b) ePPi levels in various ATDC5 
clonal cell lines at day 28 (nonmineralizing hypertrophy) of chondro-
genic differentiation. (c) ePPi levels in various ATDC5 clonal cell lines 
at day 35 (mineralization) of chondrogenic differentiation. WT, P5T, 
P5L, and M48T are independent clonal cell lines of stably transduced 
ATDC5 cells exhibiting a 1:1 transcript level ratio of endogenous ank to 
transduced ank and twice as much Ank protein as untransduced cells. 
At least three independent clones for each cell line were evaluated; 
results presented are from single clones and are representative of other 
clones for each cell line. Inorganic pyrophosphate levels for untrans-
duced ATDC5 cells and empty vector were comparable. n = 9; *P ≤ 
0.05. (d) The fold change in the expression of ank mRNA as deter-
mined by real-time RT-PCR at various times of chondrogenesis. Black 
bars, day 14 (proliferation); grey bars, day 28 (nonmineralizing hypertro-
phy); white bars, day 35 (mineralizing hypertrophy). Note increase of 
expression in ank under mineralizing conditions, which is consistent 
with the dramatic increase in ePPi in transduced cells at day 35 of cul-
ture.Available online http://arthritis-research.com/content/8/6/R164
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markers of the hypertrophic phenotype in nonmineralizing
hypertrophic cells. We examined expression levels for
col10a1, the classic extracellular matrix marker of hypertrophic
chondrocytes, for osteopontin, a secreted glycoprotein that is
a marker of terminal differentiation [26,27], and for runx2
(cbfa1), a transcription factor that is expressed in prehyper-
Figure 4
Alkaline phosphatase and nucleotide pyrophosphatase phosphodiesterase activity in transduced clones Alkaline phosphatase and nucleotide pyrophosphatase phosphodiesterase activity in transduced clones. Enzyme activities were measured in trans-
duced clones at day 14 (proliferation), at day 28 (nonmineralizing hypertrophy), and at day 35 (mineralization). Empty, uncloned cells transduced 
with pLNCX vector; WT, wild-type ank. For alkaline phosphatase (AP) measurements, the units of enzyme were determined by first subtracting the 
optical density reading of a blank from diluted samples at 2 minutes. The result of this calculation was then subtracted from a similar calculation per-
formed on samples determined at time point 0. Levels of AP are negligible at day 14 of culture and increase at day 28. Consistent with previous 
studies [8], AP activity is much higher in cells at day 35 of culture during mineralization. Although AP activity is higher for cells overexpressing WT 
ank compared with cells transduced with empty vector at days 28 and 35 of culture, cells expressing mutant ank constructs did not demonstrate AP 
activity that was significantly different from cells transduced with WT ank. Nucleotide pyrophosphatase phosphodiesterase (NPP) activity for each 
sample were determined by comparison with the standard curve of p-nitrophenol and expressed as units, where one unit is equivalent to 1 μmol sub-
strate hydrolyzed per hour. With the exception of the cell line transduced with the P5L mutant, all transduced lines exhibited NPP activity that was 
comparable with cells transduced with empty vector only. AP and NPP activities for untransduced cells and empty vector were comparable. n = 9; 
*P ≤ 0.05. At least three independent clones for each cell line were evaluated; results presented are from single clones and are representative of 
other clones for each cell line.Arthritis Research & Therapy    Vol 8 No 6    Zaka et al.
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trophic and hypertrophic chondrocytes [28,29]. col10a1
expression was almost threefold greater in cells that overex-
pressed wild-type ank than in cells transduced with empty
vector. In cells transduced with mutant ank constructs, how-
ever, the expression of col10a1 was significantly reduced in
comparison with cells overexpressing wild-type ank and was
moderately reduced in comparison with levels expressed by
cells that were transduced with empty vector only (Figure 6a).
The expression of osteopontin was not significantly different
among the transduced cells in nonmineralizing conditions (Fig-
ure 6b). Finally, the expression of runx2 was essentially the
same for cells transduced with either wild-type ank or with
mutant ank constructs, and was not statistically different from
the level of runx2 expressed by cells transduced with empty
vector only (Figure 6d). Taken together, these results suggest
that most markers of the hypertrophic phenotype such as AP,
osteopontin, and runx2 are unaffected by expression of mutant
ank, although overexpression of wild-type ank resulted in an
increase in the expression of col10a1.
Mineralization in ATDC5 cells transduced with wild-type 
and mutant ank
To determine whether transduced cells cultured under miner-
alizing conditions were competent to undergo mineralization,
cells were cultured in a mineralization medium in 3% CO2 (see
Materials and methods)as previously described [8]. At 35
days of culture, the cells were then processed for analysis of
the nature of the mineral phase deposited by all cell lines,
including cells expressing mutant Ank molecules. Similar to
the cells overexpressing wild-type Ank, the mineral to matrix
ratio for cells expressing mutant Ank molecules exhibited low
crystallinity compared with those cells transduced with empty
vector only (data not shown). In all cases, however, Fourier
transform IR analyses of the mineral phase indicated that only
basic calcium phosphate was deposited. This finding is prob-
ably a result of the high AP activity in the cell lines during min-
eralization. With respect to the P5L cell line, the hydrolysis of
the NPP-driven excess in ePPi by AP is probably also respon-
sible for the deposition of basic calcium phosphate in this cell
line.
Discussion
Recent studies of Ank in a variety of model systems have sug-
gested that the expression of Ank is intimately involved in the
regulation of cartilage mineralization and that, at the very least,
this regulation includes a triad of constituents: Ank, AP, and
isoforms of nucleotide NPP, especially the NPP1 isoform (for
a review, see [30]). Human ANK and murine Ank exhibit almost
98% homology at the protein level, with complete conserva-
tion of charge and polarity among substituted residues. For
this reason, we decided to utilize a mouse cell line for our stud-
ies and to prepare mutations in ank in the context of the mouse
cDNA sequence. Use of the ATDC5 cell line also enabled us
to evaluate the effect of overexpression of Ank and expression
of mutant Ank on hypertrophy – a point of interest in light of the
fact that Uzuki and colleagues recently observed that ANKH
immunoreactivity in chondrocytes derived from patients with
idiopathic CPPD disease reached maximum levels in areas of
affected articular cartilage occupied by chondrocytes exhibit-
ing expression of markers of hypertrophy [5].
In the studies described herein, we chose to only modestly
overexpress wild-type and mutant Ank in order to create a sta-
ble dominant-negative environment in which to evaluate PPi
elaboration, to evaluate AP and NPP activity, and to evaluate
expression of markers of hypertrophy in transduced cells. PPi
analyses in the Ank mutants indicated that only the P5L mutant
generated more ePPi than any other mutant or wild-type Ank
transduced cells at the proliferative and nonmineralizing hyper-
trophic stages of differentiation. This line also consistently dis-
played greater NPP activity at all stages of maturation than any
other cell line. Our studies suggest that the increase in ePPi in
the P5L cell line is probably a direct reflection of the NPP activ-
ity exhibited by this mutant. These observations are consistent
with previous studies showing that Ank regulates PPi levels in
coordination with the PPi-generating activity that is specifically
contributed by NPP1 [6]. The P5L mutation is unique among
the two proline mutations at the 5 position studied here – in
that the proline residue is substituted with a neutral, nonpolar
amino acid, in contrast to the P5T mutant in which proline is
substituted with a polar residue. How this fact may affect the
Figure 5
Levamisole treatment of the P5L cell line increases elaboration of extracellular inorganic pyrophosphate Levamisole treatment of the P5L cell line increases elaboration of extracellular inorganic pyrophosphate. (a) Treatment of the P5L-transduced cell 
line with levamisole results in a dramatic reduction in alkaline phosphatase (AP) activity. (b) Treatment with levamisole increases extracellular inor-
ganic pyrophosphate (ePPi) in P5L-transduced cells. n = 3; *P ≤ 0.05.Available online http://arthritis-research.com/content/8/6/R164
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structure of the P5L mutant Ank is presently unclear and must
await the studies of Ank transmembrane topology that are cur-
rently underway in our laboratory.
We also investigated the steady-state mRNA expression of
several hypertrophy-related genes in our ATDC5 cells trans-
duced with wild-type and mutant ank. While the course of dif-
ferentiation appeared to be undisturbed with regard to
expression of markers of chondrocyte proliferation and differ-
entiation such as sox9 and col2a1, we were able to observe
subtle differences in the expression of col10a1 in the trans-
duced cells that overexpressed wild-type ank. Under nonmin-
eralizing hypertrophic conditions, cells overexpressing wild-
type ank demonstrated levels of expression of col10a1 that
were twofold to threefold higher than levels in cells transduced
with empty vector only. Cells expressing mutant Ank  con-
structs, however, did not exhibit any significant change in
expression of col10a1 when compared with cells transduced
with empty vector.
Previous in vitro studies of the impact of dominant mutations
in ANKH on the function of the ANK protein were performed
Figure 6
Real-time RT-PCR analyses of hypertrophic markers in transduced lines (day 28) cultured under nonmineralizing conditions Real-time RT-PCR analyses of hypertrophic markers in transduced lines (day 28) cultured under nonmineralizing conditions. RNA levels were nor-
malized to expression of β-actin. (a) Expression of col10a1 in transduced lines. Expression is higher than empty vector in cells overexpressing wild-
type (WT) ank (*P ≤ 0.05); however, in cells expressing mutant ank, expression levels of col10a1 are equivalent to empty vector. (b) Expression of 
osteopontin in transduced lines. Expression of all transduced cells is lower than empty vector, but not significantly different among cell lines that 
express mutant ank versus cell line overexpressing WT ank. (c) Expression of runx2 (cbfa1) in transduced lines. Expression is equivalent for all trans-
duced lines and not significantly different from the expression of runx2 in cells transduced with empty vector only. n = 6. At least three independent 
clones for each cell line were evaluated; results presented are from single clones and are representative of other clones for each cell line.Arthritis Research & Therapy    Vol 8 No 6    Zaka et al.
Page 12 of 13
(page number not for citation purposes)
on transfected COS cells with constructs containing the inser-
tion of four amino acids mutant and the M48T mutant [15]. The
familial mutations did not significantly alter iPPi levels, and
ePPi levels were not examined. To explain the lack of impact
on iPPi observations, it was hypothesized that, in contrast to
the ank/ank recessive mouse mutant, the dominant human
CPPD disease mutations might act as gain-of-function alleles
that would moderately increase ePPi levels over time, leading
to subtle abnormalities that have a minor and cumulative
impact on articular cartilage homeostasis [15].
Recent studies of transient transfection of a familial (P5L [17])
ANKH mutation and two ANKH variants (-4 bp, 5' untranslated
region [31] and deletion of E490 [15]) in an immortalized
human chondrocyte cell line (CH-8) demonstrated an increase
in the transcription and translation of ANK. Among the two
missense ANKH mutants studied, neither the P5L mutant nor
the M48T mutant demonstrated an increase in ePPi elabora-
tion [31]. This effect may, in part, be due to the fact that the
studies were performed in an immortalized cell line of human
articular chondrocytes that elaborates large amounts of tumor
necrosis factor alpha [32], a cytokine reported to inhibit the
elaboration of PPi in articular chondrocytes and cartilage
explants [33] and shown to dramatically decrease the expres-
sion of ank mRNA in cultured rat chondrocytes [34]. Interest-
ingly, this same study explored the expression of type X
collagen in order to determine whether ANKH variants had the
potential to stimulate hypertrophic differentiation in the trans-
fected immortalized articular chondrocytes. Only those cells
expressing the P5L variant appeared to induce the expression
of type X collagen [31]. Our observations of type X collagen
expression show that, among the mutant constructs
expressed in transduced cells, the P5L mutant cell line
showed the highest level of type X collagen expression; how-
ever, all mutant cell lines expressed considerably less col10a1
than did cells overexpressing wild-type ank.
While the various in vitro studies of Ank overexpression on PPi
transport activity consistently demonstrate an increase in ePPi
levels (or a decrease in iPPi levels) [2,6,7,15,31], there is a
notable lack of agreement among studies utilizing the CPPD
Ank mutations. This lack of consensus illustrates the limita-
tions of in vitro systems, especially with respect to the availa-
bility of suitable in vitro model systems for the study of
diseases of articular cartilage. Future studies of Ank mutations
in animal models may illuminate the role of the CPPD-causing
mutations on the transport of PPi and the pathological miner-
alization of articular cartilage.
Conclusion
In conclusion, we have stably transduced ATDC5 cells with
wild-type and mutant cDNA ank  constructs and have
observed that, among the missense mutations, only the P5L
mutant resulted in increased activity of NPP and resulted in
increased elaboration of ePPi at the proliferative and nonmin-
eralizing hypertrophic stages of differentiation. This effect was
tempered during the mineralization phase when AP activity
was high in all transduced cells.
We also observed that modest overexpression of ank may
have subtle effects on chondrocyte maturation. Although this
is the first report of a gain-of-function in one of the familial
chondrocalcinosis-causing mutations, as previously hypothe-
sized [15], it is not clear why the two other mutations in Ank
(P5T and M48T) did not exhibit this effect. The increased ePPi
elaboration in the P5L mutant appears to be driven by the
excess NPP activity exhibited by this cell line (and other inde-
pendent cell lines expressing this mutation). This observation
may allude to the possibility of increased interaction between
the P5L mutant molecule and NPP. The evidence for interac-
tion between NPP and Ank is compelling [6,35,36]. Whether
mutations in Ank may alter the affinity of potential interaction
between these two proteins is intriguing and warrants further
investigation.
It is also not clear at this time whether our observations reflect
the state of ePPi elaboration in familial CPPD patients bearing
mutations in ANKH. CPPD disease is a disease of articular
cartilage that normally does not undergo mineralization, and
several reports suggest that the pathological mineralization of
articular cartilage in idiopathic chondrocalcinosis may occur in
the context of hypertrophic differentiation [5,25]. Interestingly,
radiological examination of joints from familial CPPD disease
patients indicates that crystal deposition precedes joint
degeneration. Consequently, the state of articular cartilage dif-
ferentiation with respect to markers of hypertrophy is unknown
in patients suffering from familial chondrocalcinosis. Our
observations of ePPi elaboration during the proliferative and
nonmineralizing phases of chondrocyte hypertrophy may
therefore hold some relevance in studies of the impact of
ANKH mutations in dominantly inherited CPPD disease.
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